A NOVEL DIAGNOSTIC AND PROGNOSTIC BIOMARKER PANEL FOR MULTIPLE MYELOMA

EHA Library, Zhang Liangjun, 4209744

INTEGRATION OF DEMOGRAPHIC VARIABLES AND DISEASE BURDEN INDICATORS WITH SPECIFIC BONE BIOMARKERS MAY PREDICT THE PRESENCE OF IMAGING-DETECTED LYTIC LESIONS

EHA Library, Patricia García Ramírez, 4209746

ROLE AND MECHANISM OF MULTIPLE MYELOMA CELLS IN REGULATING MACROPHAGE POLARIZATION AND THE ANTITUMOR EFFECT VIA ENO1

EHA Library, Zhaoyun Liu, 4209747

GEOGRAPHIC VARIABILITY IN HEALTHCARE BURDEN OF MULTIPLE MYELOMA IN SPAIN: TRENDS IN HOSPITALIZATION AND MORTALITY (2016-2023).

EHA Library, Ane Brieva Lopez, 4209748

GUT DERIVED METABOLIC PROFILING OF MGUS AND MYELOMA PATIENTS

EHA Library, Catherine Chinnery, 4209749

GLYCOSYLATION SINGLE-CELL TRANSCRIPTOMIC PROFILING DECODES DRIVER MECHANISMS OF CIRCULATING PLASMA CELLS IN MULTIPLE MYELOMA

EHA Library, Xiaoyan Qu, 4209753

SEX INFLUENCES THE PROGNOSTIC IMPACT OF TUMOR PATHWAYS IN MULTIPLE MYELOMA

EHA Library, Mobina Shrestha, 4209761

IMMUNOPHENOTYPIC FACTORS INFLUENCING THE CLINICAL COURSE OF MULTIPLE MYELOMA

EHA Library, Azat Karabekov, 4209764

EVOLUTION OF PHOSPHATAEMIA AND SIGNALLING OF THE HORMONE FGF23 IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: A POST-HOC STUDY

EHA Library, Manon Sapet, 4209765

AGE-RELATED LOSS OF THE Y CHROMOSOME DRIVES MALE-BIASED CANCER BURDEN AND ADVERSE OUTCOMES

EHA Library, Liansheng Zhang, 4209766

BASELINE PROLIFERATION ACTIVITY IDENTIFIES PATIENTS AT HIGHER RISK OF EARLY RELAPSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Mobina Shrestha, 4209767

REDOX STATUS AND DNA DAMAGE RESPONSE NETWORK IN THE TRANSFORMATION PROCESS OF MYELOMAGENESIS

EHA Library, Panagiotis Malamos, 4209769

DIAGNOSTIC PRACTICES AND BARRIERS OF HIGH-RISK MULTIPLE MYELOMA IN ENGLAND

EHA Library, Hannah McNally, 4209770

TRIAL IN PROGRESS: A PHASE 3 STUDY COMPARING AZD0120, A BCMA/CD19 DUAL-TARGETING CAR-T CELL THERAPY, VERSUS STANDARD REGIMENS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (DURGA-4)

EHA Library, Hang Quach, 4209774

PHASE 3 EMN39/LUMYNA LINKER-MM6 STUDY DESIGN: DARATUMUMAB-LENALIDOMIDE-DEXAMETHASONE (DRD) INDUCTION FOLLOWED BY LINVOSELTAMAB VS. DRD IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MYELOMA

EHA Library, Roberto Mina, 4209777

TRIAL IN PROGRESS: QUINTESSENTIAL-2—A PHASE 3 STUDY OF ARLOCABTAGENE AUTOLEUCEL VERSUS STANDARD OF CARE IN ADULT PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) EXPOSED TO LENALIDOMIDE

EHA Library, Eyal Lebel, 4209779

ASSOCIATION BETWEEN NON-CLASSICAL MUTATIONS IN THE KRAS, NRAS GENES AND EXTRAMEDULLARY DISEASE IN MULTIPLE MYELOMA

EHA Library, Maiia Soloveva, 4209780

DARATUMUMAB-CVD THERAPY IN IGM-ASSOCIATED LIGHT CHAIN AMYLOIDOSIS: CLINICAL CHARACTERISTICS AND OUTCOMES

EHA Library, Suraj Vasudevan, 4209781

EARLY MORTALITY IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIЕNTS: BIOMARKERS AND PREDICTORS IN THE REAL-WORLD SETTINGS

EHA Library, Marko Mitrovic, 4209783

A PROSPECTIVE COMPARISON OF APONERMIN-BASED REGIMENS WEEKLY VERSUS MONTHLY IN PATIENTS(PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Aijun Liu, 4209784

A REAL-WORLD STUDY ON THE EFFICACY AND SAFETY OF POMALIDOMIDE AS MAINTENANCE THERAPY FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Ling Qin, 4209786

CLINICAL SPECTRUM AND PATHOGENETIC MECHANISMS OF LIVER DYSFUNCTION IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE: A MULTICENTER STUDY AND NOVEL MURINE MODELS

EHA Library, Yi Liu, 4209788

DISTINCT CLINICAL FEATURES OF MULTIPLE MYELOMA WITH T(11;14): A POST HOC ANALYSIS OF PROSPECTIVE OBSERVATIONAL STUDY FOR MULTIPLE MYELOMA IN JAPAN (JSH-MM-15)

EHA Library, Taku Tsukamoto, 4209792

ANITOCABTAGENE AUTOLEUCEL CLINICAL TRIAL MANUFACTURING EXPERIENCE IN PATIENTS WITH RELAPSED/REFRACTORY OR NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, María-Victoria Mateos, 4209802

REAL-WORLD DATA INDICATE THAT IXAZOMIB-LENALIDOMIDE-DEXAMETHASONE MAY NOT BE INFERIOR TO DARATUMUMAB-LENALIDOMIDE-DEXAMETHASONE IN ELDERLY RELAPSED/REFRACTORY MYELOMA PATIENTS

EHA Library, Hermina Sánta, 4209806

RURALITY AND ITS EFFECT ON TREATMENT AND SURVIVAL OF MULTIPLE MYELOMA IN AUSTRALIA:A STUDY FROM THE AUSTRALIA AND NEW ZEALAND MYELOMA AND RELATED DISEASES REGISTRY (ANZ MRDR)

EHA Library, Benjamin Reardon, 4209807

DETERMINANTS OF OUTCOMES IN MULTIPLE MYELOMA: A COMPARATIVE ANALYSIS OF SUPER-RESPONDERS VS. EARLY RELAPSERS

EHA Library, Magaly Valeria Escobedo Cruz, 4209808

CYTOGENETIC TESTING IN AL AMYLOIDOSIS IN ROUTINE CLINICAL PRACTICE, A POPULATION-BASED STUDY

EHA Library, Flores Weverling, 4209809

DELAYED AND ATYPICAL NEUROTOXICITY FOLLOWING B-CELL MATURATION ANTIGEN-DIRECTED CHIMERIC ANTIGEN RECEPTOR-T CELL THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Derek Tai, 4209810

DESIGN OF THE PHASE 2 ALANIS STUDY: BELANTAMAB MAFODOTIN IN COMBINATION WITH BORTEZOMIB, CYCLOPHOSPHAMIDE, AND DEXAMETHASONE (VCD) IN PATIENTS WITH NEWLY DIAGNOSED AMYLOID LIGHT CHAIN AMYLOIDOSIS

EHA Library, Efstathios Kastritis, 4209812

SELINEXOR, BORTEZOMIB AND DEXAMETHASONE SHOWS EFFICACY IN HEPTA-REFRACTORY MULTIPLE MYELOMA - A MULTICENTER ANALYSIS

EHA Library, Maximilian Al-Bazaz, 4209814

OUTCOMES OF PATIENTS WITH INADEQUATE EARLY RESPONSE TO DARATUMUMAB UPFRONT THERAPY

EHA Library, Foteini Theodorakakou, 4209816

REAL-WORLD EVALUATION OF INTRAVENOUS IMMUNOGLOBULIN USE IN COMBINATION WITH BISPECIFIC ANTIBODIES IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Vincent Rajkumar, 4209820

UPDATED RESULTS FROM THE PHASE 2 IZALCO STUDY: EFFICACY AND SAFETY OF ISATUXIMAB SUBCUTANEOUS PLUS CARFILZOMIB AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Marcelo Capra, 4209821

REAL‑WORLD CHARACTERISTICS, TREATMENT PATTERNS AND OUTCOMES OF PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA IN CHINA TREATED WITH FIRST-LINE DARATUMUMAB-BASED REGIMENS DVRD AND DRD

EHA Library, Yating Li, 4209822

A REAL‑WORLD COMPARISON OF DARATUMUMAB PLUS DCEP VERSUS OTHER TARGETED REGIMENS IN RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE

EHA Library, Xuzhao Zhang, 4209827

REAL-WORLD COMPARISON OF UPFRONT PLERIXAFOR PLUS G-CSF VERSUS CYCLOPHOSPHAMIDE-BASED MOBILIZATION IN MULTIPLE MYELOMA: A SINGLE-CENTER STUDY FROM CHINA

EHA Library, Xiaoyan Han, 4209831

REAL WORLD OUTCOMES OF YOUNG MULTIPLE MYELOMA PATIENTS AND FACTORS INFLUENCING OUTCOMES: A SINGLE CENTRE EXPERIENCE IN INDIA

EHA Library, Souvik Saha, 4209832

BONE MARROW SUVMAX ON 18F-FDG PET / CT REFLECTS DISEASE BURDEN AND IMMUNOSUPPRESSIVE MICROENVIRONMENT IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Liansheng Zhang, 4209833

EXPERT CONSENSUS ON DEFINING PROGNOSTIC FACTORS AND TREATMENT-EFFECT MODIFIERS IN MULTIPLE MYELOMA

EHA Library, Karthik Ramasamy, 4209835

REAL‑WORLD OVERALL SURVIVAL IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (MM) IN TAIWAN TREATED WITH AND WITHOUT DARATUMUMAB‑BASED THERAPY

EHA Library, Shih-Pei Shen, 4209836

LAGOON (OP-115): A NON-INTERVENTIONAL STUDY OF MELPHALAN FLUFENAMIDE (MELFLUFEN) PLUS DEXAMETHASONE IN PATIENTS WITH RELAPSED AND/OR REFRACTORY MULTIPLE MYELOMA IN SPAIN ACCORDING TO APPROVED LABEL

EHA Library, Enrique M. Ocio, 4209837

REAL-WORLD SAFETY AND EFFICACY OF APONERMIN AND DARATUMUMAB-BASED REGIMENS IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Da Gao, 4209839

AUTOLOGOUS STEM CELL TRANSPLANTATION WITHOUT CRYOPRESERVATION IN MULTIPLE MYELOMA: FEASIBILITY AND LONG-TERM OUTCOMES IN A MOROCCAN RESOURCE-LIMITED SETTING

EHA Library, Ikram Sadki, 4209840

USING MINIMAL RESIDUAL DISEASE AS A SURVIVAL PREDICTOR FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Aashal Shah, 4209842

THE ROLE OF KINETICS OF HEMATOLOGIC RESPONSE IN MULTIPLE MYELOMA WITH OBVIOUS RENAL IMPAIRMENT

EHA Library, Aijun Liu, 4209845

EVALUATING THE CLINICAL BENEFIT OF ANTI-CD38 THERAPY IN MULTIPLE MYELOMA USING ESMO-MCBS:H AND ASCO-VF

EHA Library, Bushra Salman, 4209847

LISAFTOCLAX COMBINED WITH IXAZOMIB AND DEXAMETHASONE AFTER CART FOR MAINTENANCE THERAPY IN TRANSPLANT-INELIGIBLE RELAPSED/REFRACTORY HIGH-RISK MULTIPLE MYELOMA : TWO CASE REPORTS AND LITERATURE REVIEW

EHA Library, Shukai Qiao, 4209848

DEPRESSION AND ANXIETY FOLLOWING MULTIPLE MYELOMA:   A DANISH NATIONWIDE REGISTER-BASED COHORT STUDY

EHA Library, Klara Frederikke Koue Rydahl, 4209850

GENE-DRIVEN MONOCLONAL GAMMOPATHY/LYMPHOMA EVOLUTION IN SCHNITZLER SYNDROME: EVIDENCE FOR AN ALTERNATIVE AUTOINFLAMMATORY–ONCOGENIC AXIS

EHA Library, Ferenc Sipos, 4209750

NOVEL ALTERNATIVE SPLICE VARIANTS OF GENES ENCODING LYSOSOME-ASSOCIATED MEMBRANE PROTEINS 1 AND 2 (LAMP1 AND LAMP2) IN MULTIPLE MYELOMA, REVEALED BY COMBINING NEXT-GENERATION AND NANOPORE SEQUENCING

EHA Library, Evangelos Terpos, 4209751

COMPARATIVE TRANSCRIPTOMIC PROFILING OF IGG AND IGA-PRODUCING HUMAN MULTIPLE MYELOMA CELL LINES REVEALS ISOTYPE-SPECIFIC GENE EXPRESSION SIGNATURES

EHA Library, Evangelos Terpos, 4209752

SINGLE-CENTER RETROSPECTIVE STUDY OF CYTOGENETIC ABNORMALITIES IN PATIENTS WITH MONOCLONAL GAMMOPATHY OF UNDETERMINED SIGNIFICANCE

EHA Library, Ernesto Manuel Talegón de la Fuente, 4209754

PLATELET AGGREGATION AND THROMBIN GENERATION IN MULTIPLE MYELOMA: A PROSPECTIVE STUDY

EHA Library, Mario Biglietto, 4209755

SERUM PENTRAXIN-3 LEVELS AS A POTENTIAL BIOMARKER FOR THROMBOSIS RISK AND TREATMENT RESPONSE IN NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Seda Yilmaz, 4209756

THE ABUNDANCE AND THERAPEUTIC POTENTIAL OF LIPID DROPLETS IN MULTIPLE MYELOMA

EHA Library, Stefania Iliana Tziola, 4209757

INTRATUMORAL MICROBIOTA IN B-CELL LYMPHOMA AND MULTIPLE MYELOMA: AN EXPLORATORY STUDY

EHA Library, María Linares, 4209759

SURVIVAL OF MULTIPLE MYELOMA AND PLASMA CELL NEOPLASMS: A POPULATION-BASED STUDY IN THE PROVINCE OF GIRONA, SPAIN (1994-2020)

EHA Library, Kleber Garrochamba, 4209760

EXPORTIN-1 INHIBITION MODULATES MONOCYTIC DIFFERENTIATION AND TUMOR-ASSOCIATED MACROPHAGE FUNCTION IN THE MULTIPLE MYELOMA TUMOR MICROENVIRONMENT

EHA Library, Kereshmeh Tasbihi, 4209762

DECIPHERING THE CROSSTALK BETWEEN DNA DAMAGE RESPONSE NETWORK AND IMMUNE SURVEILLANCE IN MULTIPLE MYELOMA

EHA Library, Elisavet Deligianni, 4209763

PREDICTING NON-RESPONSE TO VMP USING SIMPLE BASELINE PARAMETERS IN ELDERLY MULTIPLE MYELOMA PATIENTS : A REAL-WORLD STUDY

EHA Library, Ahlem Slama, 4209768

FTO DRIVES MULTIPLE MYELOMA PROGRESSION VIA CHRM3-MEDIATED DYSREGULATION OF CALCIUM SIGNALING

EHA Library, hengyu liu, 4209771

BASELINE RDW AS A PROGNOSTIC MARKER IN ELDERLY MULTIPLE MYELOMA: A REAL-WORLD STUDY

EHA Library, Ahlem Slama, 4209772

PHASE 3 MAGNETISMM-6: ELRANATAMAB, DARATUMUMAB, AND LENALIDOMIDE VS DARATUMUMAB, BORTEZOMIB, LENALIDOMIDE, AND DEXAMETHASONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA

EHA Library, Meletios Dimopoulos, 4209773

DREAMM-15: A STUDY ASSESSING THE EFFICACY AND SAFETY OF EXTENDED DOSING OF BELANTAMAB MAFODOTIN IN COMBINATION WITH STANDARD OF CARE THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Douglas Sborov, 4209775

CEVOLUTION: A RANDOMIZED PHASE III TRIAL COMPARING THE EFFICACY AND SAFETY OF CEVOSTAMAB PLUS POMALIDOMIDE AND DEXAMETHASONE VERSUS STANDARD OF CARE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Rakesh Popat, 4209776

IMPACT OF BITE BRIDGING ON CRS KINETICS AFTER BCMA CAR-T: A MACHINE LEARNING SURVIVAL FRAMEWORK

EHA Library, Anushri Soni, 4209782

A PRELIMINARY CLINICAL STUDY ON REDUCED-DOSE TALQUETAMAB COMBINED WITH PACE REGIMEN BRIDGE BCMA CAR-T THERAPY FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA WITH MULTIPLE EXTRAMEDULLARY LESIONS

EHA Library, Yanli Feng, 4209785

STEADY-STATE MOBILIZATION WITH ON-DEMAND PLERIXAFOR AFTER CD38-ANTIBODY-BASED INDUCTION IN MULTIPLE MYELOMA PATIENTS

EHA Library, Maximilian Roehnert, 4209787

A PILOT STUDY OF ROMOSOZUMAB IN POSTMENOPAUSAL WOMEN WITH MYELOMA-RELATED BONE DISEASE AND OSTEOPOROSIS

EHA Library, Carlyn Rose Tan, 4209789

PERFORMANCE VALIDATION OF MASS SPECTROMETRY FOR URINARY BENCE JONES PROTEIN DETECTION AND ITS CLINICAL APPLICATION IN MULTIPLE MYELOMA AND AMYLOIDOSIS

EHA Library, Min Yang, 4209790

IMPACT OF PROTON PUMP INHIBITORS ON CLINICAL OUTCOMES IN NEWLY DIAGNOSED TRANSPLANT-INELIGIBLE MULTIPLE MYELOMA: A POST HOC ANALYSIS OF THE BENEFIT STUDY

EHA Library, Manon Sapet, 4209791

A PHASE 1/2, OPEN-LABEL, PLATFORM STUDY TO EVALUATE THE SAFETY AND EFFICACY OF ETENTAMIG MONOTHERAPY OR COMBINATION THERAPY IN PATIENTS WITH MULTIPLE MYELOMA

EHA Library, Karthik Nath, 4209793

LONG-TERM EFFICACY OF TALQUETAMAB IN CHINESE PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM THE PHASE 2 MONUMENTAL-1 STUDY：ANALYSIS OF 2-YEAR FOLLOW-UP

EHA Library, Gang An, 4209794

CLINICAL OBSERVATION OF DV/RBD REGIMEN IN THE TREATMENT OF FIRST-RELAPSED MULTIPLE MYELOMA

EHA Library, Haitao Meng, 4209796

REAL WORLD USE OF MELPHALAN FLUFENAMIDE (MELFLUFEN) IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: PRELIMINARY RESULTS IN 60 PATIENTS FROM THE SPANISH REGISTRY

EHA Library, David Martínez-Campuzano, 4209798

REGIONAL COMPARISONS OF REAL-WORLD OUTCOMES FOLLOWING LENALIDOMIDE AND ANTI-CD38 EXPOSURE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A PREAMBLE REGISTRY ANALYSIS IN THE US AND EUROPE

EHA Library, Karthik Ramasamy, 4209799

OCULAR TOXICITIES OF BELANTAMAB MAFODOTIN MONOTHERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Mehak Dang, 4209800

ELRANATAMAB (ELRA) SAFETY DURING STEP-UP DOSING (SUD) BY CARE SETTING IN RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)

EHA Library, Aaron Rosenberg, 4209801

PATIENT CHARACTERISTICS AND INITIAL REAL-WORLD DOSING EXPERIENCE WITH BELANTAMAB MAFODOTIN-BASED COMBINATIONS FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Elena Zamagni, 4209803

EARLY ADMINISTRATION OF TOCILIZUMAB FOR GRADE 1 CYTOKINE RELEASE SYNDROME AT FIRST FEVER SIGNIFICANTLY REDUCES THE RISK OF PROGRESSING TO A HIGHER GRADE IN PATIENTS RECEIVING CEVOSTAMAB MONOTHERAPY

EHA Library, Paula Rodríguez-Otero, 4209804

REAL-WORLD OUTCOMES OF DARATUMUMAB-LENALIDOMIDE-DEXAMETHASONE IN TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA: EXPERIENCE FROM THE RTM (REGIONAL TUSCAN MYELOMA NETWORK)

EHA Library, Irene Attucci, 4209805

THE EVOLVING OUTCOMES OF NEWLY DIAGNOSED (NDMM) HIGH-RISK CYTOGENETIC MULTIPLE MYELOMA IN CHINESE PATIENTS: A 15‑YEAR REAL‑WORLD ANALYSIS WITH US BENCHMARKING

EHA Library, Meng Shu, 4209811

PROGNOSTIC IMPACT OF BASELINE CHARACTERISTICS IN EXTRAMEDULLARY MYELOMA: A RETROSPECTIVE MULTICENTRIC ANALYSIS

EHA Library, Maria Beatrice Ferrari, 4209813

THE IMPACT OF FIRST-LINE DARATUMUMAB ON LIGHT-CHAIN AMYLOIDOSIS SURVIVAL: A REAL-WORLD ANALYSIS OF 70 PATIENTS

EHA Library, Fruzsina Szél, 4209815

ANTI-CD38 QUADRUPLET VS TRIPLET INDUCTION IN TRANSPLANT-ELIGIBLE NDMM: A BAYESIAN NETWORK META-ANALYSIS COMPARING D-VRD AND ISA-RVD

EHA Library, Shankar Biwas, 4209818

IINFECTIONS FOLLOWING COMBINED THERAPY WITH A GPRC5DXCD3 BISPECIFIC (TALQUETAMAB) OR BCMA BISPECIFIC ANTIBODIES (ELRANATAMAB/TECLISTAMAB) AND TOCILIZUMAB, IN MULTIPLE MYELOMA PATIENTS

EHA Library, Bojana Mandic, 4209819

MAINTAINED RENAL FUNCTION WITH MELFLUFEN THERAPY IN RRMM: RESULTS FROM ANALYSIS OF POOLED CLINICAL DATA

EHA Library, Fredrik Schjesvold, 4209823

INCIDENCE AND IMPACT OF FRAILTY ON TREATMENT TOLERABILITY AND QUALITY OF LIFE IN NEWLY DIAGNOSED MULTIPLE MYELOMA: A MULTICENTER PROSPECTIVE STUDY FROM THE CATALAN MYELOMA GROUP

EHA Library, Carles Tolosa Ridao, 4209824

APONERMIN+SD REGIMEN: AN EFFECTIVE AND SAFE PREFERRED BRIDGING STRATEGY BEFORE BCMA CAR-T THERAPY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA PATIENTS

EHA Library, Juan Li, 4209825

BEYOND FUNCTIONAL HIGH-RISK: ULTRA-EARLY RELAPSE AFTER AUTOLOGOUS STEM CELL TRANSPLANTATION IDENTIFIES AN EVEN HIGHER-RISK SUBGROUP IN MULTIPLE MYELOMA

EHA Library, Juan Li, 4209828

BASELINE AND EARLY DYNAMIC CHANGES OF AFR AND RAR: NOVEL AND ACCESSIBLE PROGNOSTIC BIOMARKERS IN MULTIPLE MYELOMA

EHA Library, Yongyong Ma, 4209829

DUAL-ANTIGEN-TARGETING T-CELL IMMUNOTHERAPIES FOR RELAPSE/REFRACTORY MULTIPLE MYELOMA: A SYSTEMATIC REVIEW AND META-ANALYSIS

EHA Library, Minyue Zhang, 4209830

ASSOCIATION BETWEEN EARLY RESPONSE TO TREATMENT AND LONG-TERM SURVIVAL OUTCOMES AMONG REAL-WORLD PATIENTS WITH RELAPSED/REFRACTORY (R/R) MULTIPLE MYELOMA

EHA Library, Alexander Russell, 4209834

REAL-WORLD OUTCOMES OF ELRANATAMAB IN CANADA: A CANADIAN MYELOMA RESEARCH GROUP DATABASE STUDY

EHA Library, Guido Lancman, 4209841

MULTIPLE MYELOMA IN A RESTRICTED-ACCESS HEALTHCARE SETTING: SURVIVAL OUTCOMES AND PROGNOSTIC RISK FACTORS

EHA Library, Francisca Ramirez Aspiazu, 4209843

PREDICTIVE VALUE OF HIGH-THROUGHPUT IN VITRO DRUG SENSITIVITY TESTING FOR THERAPEUTIC EFFICACY IN RELAPSED/REFRACTORY MULTIPLE MYELOMA

EHA Library, Xi Zhang, 4209844

EVOLVING OUTCOMES IN MULTIPLE MYELOMA: A 30-YEAR SINGLE CENTER REAL-WORLD EXPERIENCE.

EHA Library, Claudia Bellofiore, 4209846

METABOLIC TUMOR BURDEN ON ¹⁸F-FDG PET/CT AS AN INDEPENDENT PROGNOSTIC MARKER IN MULTIPLE MYELOMA

EHA Library, Edibe Eker, 4209849

EFFICACY ANALYSIS OF SELINEXOR-BASED REGIMENS IN THE TREATMENT OF TRIPLE-CLASS REFRACTORY OR BEYOND MULTIPLE MYELOMA WITH EXTRAMEDULLARY DISEASE: A REAL-WORLD STUDY

EHA Library, Xin Li, 4209851